Immune Therapies

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1217-1230

  Prabhala, Rao H ^a,b   Munshi, Nikhil C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYTOTOXIC AGENT; DENDRITIC CELL VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IDIOTYPIC ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; TUMOR ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL INTERACTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOBIOLOGY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY;

CELL COMMUNICATION; CLINICAL TRIALS AS TOPIC; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ACTIVE; MULTIPLE MYELOMA;

EID: 35748948402     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.011     Document Type: Review

References (83)

1. Munshi N.C. Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am 11 (1997) 51-69
2. Bouneaud C., Kourilsky P., and Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13 (2000) 829-840
3. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
4. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instabilities in human cancers. Nature 396 (1998) 643-649
5. Shammas M.A., Shmookler Reis R.J., Li C., et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 10 (2004) 770-776
6. Vonderheide R.H., Hahn W.C., Schultze J.L., et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
7. Liotta L.A., and Kohn E.C. The microenvironment of the tumour-host interface. Nature 411 (2001) 375-379
8. Simon R.M., Steinberg S.M., Hamilton M., et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19 (2001) 1848-1854
9. Zeis M., Siegel S., Wagner A., et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170 (2003) 5391-5397
10. Janssen E.M., Lemmens E.E., Wolfe T., et al. CD4 + T cells are required for secondary expansion and memory in CD8 + T lymphocytes. Nature 421 (2003) 852-856
11. Sun J.C., and Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300 (2003) 339-342
12. Shedlock D.J., and Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300 (2003) 337-339
13. Smith C.M., Wilson N.S., Waithman J., et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5 (2004) 1143-1148
14. Ernst B., Lee D.S., Chang J.M., et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11 (1999) 173-181
15. Watanabe N., Hanabuchi S., Soumelis V., et al. Human thymic stromal lymphopoietin promotes dendritic cell-mediated CD4 + T cell homeostatic expansion. Nat Immunol 5 (2004) 426-434
16. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
17. Pennington D.J., Silva-Santos B., Silberzahn T., et al. Early events in the thymus affect the balance of effector and regulatory T cells. Nature 444 (2006) 1073-1077
18. Zheng Y., Josefowicz S.Z., Kas A., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445 (2007) 936-940
19. Gavin M.A., Rasmussen J.P., Fontenot J.D., et al. Foxp3-dependent program of regulatory T-cell differentiation. Nature 445 (2007) 771-775
20. Wan Y.Y., and Flavell R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445 (2007) 766-770
21. Marson A., Kretschmer K., Frampton G.M., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445 (2007) 931-935
22. Wu Y., Borde M., Heissmeyer V., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126 (2006) 375-387
23. Ivanov I.I., McKenzie B.S., Zhou L., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126 (2006) 1121-1133
24. Acosta-Rodriguez E.V., Rivino L., Geginat J., et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8 (2007) 639-646
25. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8 (2007) 942-949
26. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8 (2007) 950-959
27. Diefenbach A., Jensen E.R., Jamieson A.M., et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
28. Stern-Ginossar N., Elefant N., Zimmermann A., et al. Host immune system gene targeting by a viral miRNA. Science 317 (2007) 376-381
29. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101 (2000) 455-458
30. Mucida D., Park Y., Kim G., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317 (2007) 256-260
31. Ono M., Yaguchi H., Ohkura N., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446 (2007) 685-689
32. Ziegler S.F. FOXP3: of mice and men. Annu Rev Immunol 24 (2006) 209-226
33. Veldhoen M., Hocking R.J., Atkins C.J., et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
34. Bettelli E., Carrier Y., Gao W., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238
35. Laurence A., Tato C.M., Davidson T.S., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26 (2007) 371-381
36. Massaia M., Bianchi A., Attisano C., et al. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex. Blood 78 (1991) 1770-1780
37. Brown R.D., Pope B., Murray A., et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98 (2001) 2992-2998
38. Xie J., Wang Y., Freeman III M.E., et al. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 101 (2003) 4005-4012
39. Mariani S., Coscia M., Even J., et al. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. Br J Haematol 113 (2001) 1051-1059
40. Maecker B., Anderson K.S., von Bergwelt-Baildon M.S., et al. Viral antigen-specific CD8 + T-cell responses are impaired in multiple myeloma. Br J Haematol 121 (2003) 842-848
41. Zinneman H.H., and Hall W.H. Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Ann Intern Med 41 (1954) 1152-1163
42. Robertson J.D., Nagesh K., Jowitt S.N., et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82 (2000) 1261-1265
43. Raje N., Gong J., Chauhan D., et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 93 (1999) 1487-1495
44. Butch A.W., Kelly K.A., and Munshi N.C. Dendritic cells derived from multiple myeloma patients efficiently internalize different classes of myeloma protein. Exp Hematol 29 (2001) 85-92
45. Ratta M., Fagnoni F., Curti A., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100 (2002) 230-237
46. Wang S., Hong S., Yang J., et al. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 108 (2006) 4071-4077
47. Dauer M., Obermaier B., Herten J., et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 170 (2003) 4069-4076
48. West M.A., Wallin R.P., Matthews S.P., et al. Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 305 (2004) 1153-1157
49. Hermans I.F., Silk J.D., Gileadi U., et al. Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells. J Immunol 178 (2007) 2721-2729
50. Prabhala R.H., Neri P., Bae J.E., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 107 (2006) 301-304
51. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4 + CD25 + T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
52. Beyer M., Kochanek M., Giese T., et al. In vivo peripheral expansion of naive CD4 + CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 107 (2006) 3940-3949
53. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007) 139-145
54. Alexandrakis M.G., Pappa C.A., Miyakis S., et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 17 (2006) 412-416
55. Brenne A.T., Ro T.B., Waage A., et al. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99 (2002) 3756-3762
56. Lynch R.G., Graff R.J., Sirisinha S., et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 69 (1972) 1540-1544
57. Yi Q., Osterborg A., Bergenbrant S., et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 86 (1995) 3043-3049
58. King C.A., Spellerberg M.B., Zhu D., et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 4 (1998) 1281-1286
59. Stritzke J., Zunkel T., Steinmann J., et al. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br J Haematol 120 (2003) 27-35
60. Bergenbrant S., Yi Q., Osterborg A., et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 92 (1996) 840-846
61. Osterborg A., Yi Q., Henriksson L., et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 91 (1998) 2459-2466
62. Rasmussen T., Hansson L., Osterborg A., et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 101 (2003) 4607-4610
63. Bertinetti C., Zirlik K., Heining-Mikesch K., et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res 66 (2006) 4496-4502
64. Massaia M., Borrione P., Battaglio S., et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 94 (1999) 673-683
65. Coscia M., Mariani S., Battaglio S., et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia 18 (2004) 139-145
66. Neelapu S.S., Munshi N.C., Jagannath S., et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36 (2005) 315-323
67. Lim S.H., and Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 83 (1999) 215-222
68. Titzer S., Christensen O., Manzke O., et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 108 (2000) 805-816
69. Liso A., Stockerl-Goldstein K.E., Auffermann-Gretzinger S., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 6 (2000) 621-627
70. Yi Q., Desikan R., Barlogie B., et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol 117 (2002) 297-305
71. Reichardt V.L., Okada C.Y., Liso A., et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 (1999) 2411-2419
72. Reichardt V.L., Milazzo C., Brugger W., et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 88 (2003) 1139-1149
73. Bendandi M., Rodriguez-Calvillo M., Inoges S., et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma 47 (2006) 29-37
74. Eggert A.A., Schreurs M.W., Boerman O.C., et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59 (1999) 3340-3345
75. Morse M.A., Coleman R.E., Akabani G., et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 (1999) 56-58
76. Fong L., Brockstedt D., Benike C., et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166 (2001) 4254-4259
77. Palucka K.A., Taquet N., Sanchez-Chapuis F., et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160 (1998) 4587-4595
78. Gong J., Koido S., Chen D., et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99 (2002) 2512-2517
79. Spisek R., Kukreja A., Chen L.C., et al. Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204 (2007) 831-840
80. Ho S.B., Niehans G.A., Lyftogt C., et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53 (1993) 641-651
81. Treon S.P., Maimonis P., Bua D., et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 96 (2000) 3147-3153
82. Takahashi T., Makiguchi Y., Hinoda Y., et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 153 (1994) 2102-2109
83. Zendman A.J., Ruiter D.J., and Van Muijen G.N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 194 (2003) 272-288